What about the following CRISPR patent problem?

https://www.forbes.com/sites/jacobsherkow/2017/02/21/how-muc...

http://www.nature.com/news/why-the-crispr-patent-verdict-isn...

This could discourage smaller companies from picking it up (ex. to build upon it, from which in the long run everyone will profit, see open-source) and make CRISPR-based treatments more expensive / unavailable (ex. large companies owning the patents artificially inflating the price, may be even more than the old technology it replaces).